Grand Mal Seizure Treatment Market Forecast 2024-2033: Growth Rate, Drivers, And Trends
Posted by ramtbrc on February 22nd, 2024
The Grand Mal Seizure Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Grand Mal Seizure Treatment Market:
https://www.thebusinessresearchcompany.com/report/grand-mal-seizure-treatment-global-market-report
According to The Business Research Company’s Grand Mal Seizure Treatment Global Market Report 2024, The grand mal seizure treatment market size has grown strongly in recent years. It will grow from .91 billion in 2023 to .02 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to neurological understanding, medical advancement, medication development, development of seizure classification, legal and social advocacy.
The grand mal seizure treatment market size is expected to see strong growth in the next few years. It will grow to .48 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to genetic research and precision medicine, telemedicine for remote care, regulatory changes in accessibility, enhanced brain imaging techniques, holistic approach in treatment. Major trends in the forecast period include global advocacy for epilepsy awarenes, patient-centered care models, expanded research in seizure genetics, community support networks, non-pharmacological treatment approaches.
The high prevalence of epilepsy is expected to propel the growth of the grand mal seizure treatment market going forward. Epilepsy is a neurological disorder in which the patient suffers from recurring seizures. Grand mal seizures are often caused by epilepsy and produce violent seizures. Increasing prevalence increases the need for better treatment, which can be achieved using grand mal seizure treatment. For instance, in February 2023, according to the World Health Organization, a Switzerland-based public health agency of the United Nations, approximately 50 million people in the world were suffering from epilepsy, making it one of the most prevalent neurological conditions worldwide. Every year, about 5 million people are diagnosed with epilepsy. Therefore, the high prevalence of epilepsy is driving the growth of the grand mal seizure treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12349&type=smp
The grand mal seizure treatment market covered in this report is segmented –
1) By Type: Barbiturates, Hydantoin, Phenyltriazine, Iminostilbenes, Benzodiazepines, Aliphatic Carboxylic Acids, Other Types
2) By Diagnosis: Magnetic Resonance Imaging (MRI), Electroencephalogram (EEG), Blood Tests, Computed Tomography (CT), Other Diagnosis
3) By Treatment: Antiepileptic Drugs, Surgery, Vagus Nerve Stimulation, Ketogenic Diet, Other Treatments
4) By End Users: Academic And Research Centers, Neurological Centers, Hospitals, Other End Users
Major companies operating in the grand mal seizure treatment market are developing new products such as anti-epilepsy medications to gain a competitive edge in the market. Anti-epilepsy medications, also known as antiepileptic drugs (AEDs) or anticonvulsants, are a class of pharmaceuticals designed to manage and treat epileptic seizures and related disorders. For instance, in January 2023, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched the Topiramate extended-release capsules in the U.S. market. The generic anti-epilepsy medication is available in strengths of USP 25 mg, 50 mg, and 100 mg, making Zydus the first company to receive final approval and introduce the product in these strengths. The capsules are indicated for epilepsy treatment, specifically as initial monotherapy for patients aged six and older with partial-onset or primary generalized tonic-clonic seizures, as well as for migraine prophylaxis in patients aged 12 and older.
The grand mal seizure treatment market report table of contents includes:
1. Executive Summary
2. Grand Mal Seizure Treatment Market Characteristics
3. Grand Mal Seizure Treatment Market Trends And Strategies
4. Grand Mal Seizure Treatment Market - Macro Economic Scenario
5. Global Grand Mal Seizure Treatment Market Size and Growth
.
32. Global Grand Mal Seizure Treatment Market Competitive Benchmarking
33. Global Grand Mal Seizure Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Grand Mal Seizure Treatment Market
35. Grand Mal Seizure Treatment Market Future Outlook and Potential Analysis
36. Appendix
